Macroaxis: Personalized Investing
Simple Personalized Investing

SP 500   1,666   1.18  Index Moved Down -0.07%
GILD AMGN BIIB CELG Cigarettes Macroaxis 20 Market Drivers Conservative 
United States GSPC USD ...  |  Investing Themes


Processing
Collecting data for XNPT

Xenoport quote and profile

 
 Companies |  Insiders  | Dashboard  
     
5.72
  
STOCK
0.00  No Change   0.00%  
Year To Date
4.3112.98
Last 1 Month(s)
5.727.31
May 21 2013 

Diversification Suggestion

Use Xenoport to protect against small markets fluctuations. The stock experiences normal downward trend, but the immediate impact on correlations cannot be determined at the moment
Analyze Xenoport Inc Trend or Check current 30 days Xenoport correlation with market (S&P 500)
1 Month Beta 3.59  
Highest Price:  
Lowest Price:  
7.31  
5.72  
April 23 2013 
May 20 2013 
As market goes up, the company is expected to significantly outperform it. However, if the market returns are negative, Xenoport will likely underperform.
Xenoport Inc Large BetaXenoport Inc Beta Legend
XNPT United States Nasdaq
Xenoport Inc
Healthcare
Biotechnology
Benchmark S&P 500
http://www.xenoport.com
Contact Number: 408. 616. 7200
Currency: USD - US Dollar
Traded on NASDAQ
    
Current Valuation204.84 M
Shares Outstanding47.4 M
Number of Shares Shorted2.06 M
Revenue11.7 M
 United States Nasdaq   0.97 % Macroaxis: 0.97 Moved Up  
 
 United States Russel   0.17 % Macroaxis: 0.17 Moved Up  
 
 United States NYSE   0.12 % Macroaxis: 0.12 Moved Up  
 
 thisGreen XNPT XNPT agains markets  0.00 % No Change  
 United States SP 500   0.07 % Macroaxis: 0.07 Moved Down  
 
Compare to Competition Get Alpha   Get Advice

Xenoport Leadership

Ronald Barrett Co-Founder, CEO and Director, Ph.D
Gregory Bates Senior Vice President - Regulatory Affairs and Quality
William Harris CFO, Principal Accounting Officer and Sr. VP of Fin., MBA
Vincent Angotti COO and Executive VP, MBA

Xenoport Price and Market Media

The median price of Xenoport for the period between Sun, Apr 21, 2013 and Tue, May 21, 2013 is 6.16 with a coefficient of variation of 7.2. The daily time series for the period is distributed with a sample standard deviation of 0.45, arithmetic mean of 6.32, and mean deviation of 0.37. The Stock received some media coverage during the period.
Xenoport         SP 500
Price Growth (%)
 
1
Bearish MACD for XenoPort Inc. Tale of the Tape NASDAQ.com04/23/2013Macroaxis: News
2
Xenoport Earnings Everything You Must Know Now04/25/2013Macroaxis: News

Xenoport Summary

Xenoport Inc [XNPT] is traded on NASDAQ in USA. It is located in Xenoport, Inc.Santa Clara, CA and employs 88 people. The company currently falls under 'Small-Cap' category with current market capitalization of 271.14 M. Xenoport Inc conducts business under Healthcare sector and is part of Biotechnology industry. This company has 47.4 M outstanding shares of which 2.06 M shares are at this time shorted by private and institutional investors with about 5.6 trading days to cover.
XenoPort, Inc., a biopharmaceutical company, focuses on developing and commercializing a portfolio of internally discovered product candidates for the treatment of neurological disorders. more
Past Market
Over 30
Days
0
Out Of
100
 
Chance of
More
Than
88 %
 
Follow Xenoport with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
Add To Reader
 
Add Xenoport to your reader
 

Xenoport Research Report

Xenoport vs. Gilead

Correlation analysis and fundamentals comparison between Xenoport Inc and Gilead Sciences

Xenoport Executives

William Harris CFO, Principal Accounting Officer and Sr. VP of Fin., MBA
Vincent Angotti COO and Executive VP, MBA

Xenoport Directors

John Freund Lead Independent Director
Catherine Friedman Independent Director
Dennis Fenton Independent Director
Ernest Mario Director
Paul Berns Independent Director

Xenoport Management

Gianna Bosko Chief Admin. Officer, Sr. VP, General Counsel and Secretary
Gregory DVM Sr. VP of Regulatory Affairs and Quality

Xenoport Fundamentals

Retained Earnings vs Cash and Equivalents
Gross Profit vs Return On Equity
Retained Earnings vs Book Value Per Share
Earnings Per Share vs Return On Equity

Xenoport vs Competition

Xenoport vs. Gilead Sciences Inc
Xenoport vs. Amgen Inc
Xenoport vs. Biogen Idec Inc
Xenoport vs. Celgene Corporation
Xenoport vs. Regeneron Pharmaceuticals Inc
Xenoport vs. Alexion Pharmaceuticals Inc
Xenoport vs. Vertex Pharmaceuticals Incorporated
Xenoport vs. Illumina Inc
Xenoport vs. BioMarin Pharmaceutical Inc
Xenoport vs. Onyx Pharmaceuticals Inc

Xenoport May 21 2013 Opportunity Range

Downside Deviation6.0
Information Ratio(0.28)
Maximum Drawdown9.66
Value At Risk(7.85)
Potential Upside4.4

 
Analytics
Risk Adjusted Returns Landscape
Live Efficient Frontier
Market Correlation Analysis
Watchlist Analysis
Financial Content
Portfolio Estimation and Projections
Portfolio Theme Builder
 
 
Research Modules
Equities Backtesting Analysis
Instant Retirement Optimizer
Cross-portfolio RSS and Mobile Access
Company, fund, and ETF Directory
Financial Advisor Directory
Insider and Manager Directory
Wealth Management
 Gadgets, Widgets, and Apps          
  
 
Services And Technology
Frequently Asked Questions
Quick Product Tour
Product Technology Overview
Solution Methodology
Plans and Pricing
 
Free Investor Tools
World Market Correlations
Instant Equity Comparator
Watchlist Analysis
Position Suggestions
Equity Alpha Analysis
 
About Us
About Macroaxis
Contact Us
Product Terms Of Use
Service Privacy Policy
Advertising Opportunities
Content

Thanks for checking out Macroaxis

Tell us what you like and what you don't like. We promise we'll not only listen but write you back

Contact Us
Macroaxis is user-driven community of investors. We appreciate any feedback or comment you can provide. Please fill out our quick survey to help us provide your with a better service and user experience

Fill Out Quick Survey
Most of the functionality on our site is free to use. However we do provide premium service to sophisticated investors. Our premium subscription will give you unprecedented capabilities to optimize your portfolios using robust financial analysis toolkit, fast mean-variance optimization engine, and proven portfolio theory

Go Premium